Pharmacyclics' (PCYC +5.2%) ibrutinib has substantial commercial potential, says Needham. After...
Tuesday, June 5, 2012, 3:59 PM ETPharmacyclics' (PCYC +5.2%) ibrutinib has substantial commercial potential, says Needham. After reviewing the data, Needham sees PCYC and collaborator Johnson & Johnson (JNJ -0.1%) being in a strong position given the drug's potential as both a front-line and relapsed or refractory agent. The firm believes a single-agent Phase 3 trial in front-line elderly chronic lymphocytic leukemia cases may be possible by the end of this year.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles